Howland Capital Management’s Sarepta Therapeutics SRPT Stock Holding History

Howland Capital Management’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-1,616	Closed	-$202K	–	291
2024 Q3	$202K	Hold	1,616	–	–	0.01%	276
2024 Q2	$255K	Sell	1,616 -16	-1%	-$2.06K	0.01%	251
2024 Q1	$211K	Buy	+1,632	New	+$200K	0.01%	257
2023 Q2	–	Sell	-1,632	Closed	-$225K	–	269
2023 Q1	$225K	Hold	1,632	–	–	0.01%	248
2022 Q4	$211K	Buy	+1,632	New	+$189K	0.01%	246
2021 Q1	–	Sell	-1,932	Closed	-$329K	–	241
2020 Q4	$329K	Hold	1,932	–	–	0.02%	183
2020 Q3	$271K	Hold	1,932	–	–	0.02%	181
2020 Q2	$310K	Buy	+1,932	New	+$263K	0.02%	174

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Howland Capital Management's SRPT Position: Q4 2024 in Review

Howland Capital Management sold out of Sarepta Therapeutics (SRPT) in Q4 2024, closing a stake of 1,616 shares — an estimated $202K sold.

Howland Capital Management first reported a position in SRPT in Q2 2020 and held it in 8 quarters. The position peaked at $329K in Q4 2020. 464 funds tracked by Wall St. Rank hold SRPT as of Q4 2024.

Howland Capital Management reported no remaining Sarepta Therapeutics position as of Q4 2024 after selling out during the quarter.
Howland Capital Management sold 1,616 Sarepta Therapeutics shares in Q4 2024, an estimated $202K.
Howland Capital Management first reported a position in Sarepta Therapeutics in Q2 2020 and held it in 8 quarters.
Howland Capital Management's Sarepta Therapeutics position peaked at $329K in Q4 2020.
464 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2024.

Based on Howland Capital Management's 13F filing for Q4 2024, filed 28 Jan 2025.